Loading...

We've got a brand new version of Simply Wall St! Try it out

Invitrocue

ASX:IVQ
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IVQ
ASX
A$35M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Invitrocue Limited provides healthcare bio-analytics solutions primarily in Australia, China, Hong Kong, and Germany. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
IVQ Share Price and Events
7 Day Returns
0%
ASX:IVQ
0.8%
AU Biotechs
-1%
AU Market
1 Year Returns
-25%
ASX:IVQ
39%
AU Biotechs
12.6%
AU Market
IVQ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Invitrocue (IVQ) 0% 0% -7.7% -25% -40% -
AU Biotechs 0.8% 9.1% 19.9% 39% 156.5% 205.4%
AU Market -1% 1.8% 3.3% 12.6% 22.5% 15.5%
1 Year Return vs Industry and Market
  • IVQ underperformed the Biotechs industry which returned 39% over the past year.
  • IVQ underperformed the Market in Australia which returned 12.6% over the past year.
Price Volatility
IVQ
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Invitrocue's competitors could be found in our database.

IVQ Value

 Is Invitrocue undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Invitrocue is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Invitrocue has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Invitrocue. This is due to cash flow or dividend data being unavailable. The share price is A$0.06.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Invitrocue's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Invitrocue's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:IVQ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in SGD SGD-0.01
ASX:IVQ Share Price ** ASX (2019-08-08) in AUD A$0.06
ASX:IVQ Share Price converted to SGD reporting currency Exchange rate (AUD/ SGD) 0.936 SGD0.06
Global Biotechs Industry PE Ratio Median Figure of 140 Publicly-Listed Biotechs Companies 30.41x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Invitrocue.

ASX:IVQ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:IVQ Share Price ÷ EPS (both in SGD)

= 0.06 ÷ -0.01

-4.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Invitrocue is loss making, we can't compare its value to the Global Biotechs industry average.
  • Invitrocue is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Invitrocue's expected growth come at a high price?
Raw Data
ASX:IVQ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 82 Publicly-Listed Biotechs Companies 1.29x
Australia Market PEG Ratio Median Figure of 345 Publicly-Listed Companies 1.63x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Invitrocue, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Invitrocue's assets?
Raw Data
ASX:IVQ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in SGD SGD0.00
ASX:IVQ Share Price * ASX (2019-08-08) in AUD A$0.06
ASX:IVQ Share Price converted to SGD reporting currency Exchange rate (AUD/ SGD) 0.936 SGD0.06
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.03x
Australia Market PB Ratio Median Figure of 1,583 Publicly-Listed Companies 1.75x
ASX:IVQ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:IVQ Share Price ÷ Book Value per Share (both in SGD)

= 0.06 ÷ 0.00

-22.68x

* Primary Listing of Invitrocue.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Invitrocue has negative assets, we can't compare the value of its assets to the AU Biotechs industry average.

Next steps:

  1. Take a look at our analysis of IVQ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Invitrocue's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Invitrocue's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Invitrocue has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IVQ Future Performance

 How is Invitrocue expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invitrocue has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.9%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Invitrocue expected to grow at an attractive rate?
  • Unable to compare Invitrocue's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Invitrocue's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Invitrocue's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:IVQ Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 12.9%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:IVQ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SGD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:IVQ Past Financials Data
Date (Data in SGD Millions) Revenue Cash Flow Net Income *
2019-06-30 1 -4 -7
2019-03-31 1 -4 -7
2018-12-31 1 -4 -6
2018-09-30 1 -4 -6
2018-06-30 1 -4 -5
2018-03-31 1 -3 -4
2017-12-31 1 -2 -3
2017-09-30 1 -2 -2
2017-06-30 1 -2 -2
2016-12-31 0 -4 -21
2016-09-30 0 -4 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Invitrocue is high growth as no earnings estimate data is available.
  • Unable to determine if Invitrocue is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:IVQ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Invitrocue Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:IVQ Past Financials Data
Date (Data in SGD Millions) EPS *
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 0.00
2017-06-30 0.00
2016-12-31 -0.06
2016-09-30 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Invitrocue will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of IVQ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Invitrocue's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Invitrocue's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Invitrocue's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Invitrocue has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IVQ Past Performance

  How has Invitrocue performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Invitrocue's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Invitrocue does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Invitrocue's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Invitrocue's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Invitrocue's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Invitrocue Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:IVQ Past Revenue, Cash Flow and Net Income Data
Date (Data in SGD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.54 -6.67 6.75 0.21
2019-03-31 0.53 -6.54 6.67 0.27
2018-12-31 0.52 -6.41 6.58 0.34
2018-09-30 0.55 -5.53 5.53 0.45
2018-06-30 0.59 -4.66 4.47 0.56
2018-03-31 0.62 -3.62 3.52 0.41
2017-12-31 0.64 -2.57 2.57 0.27
2017-09-30 0.69 -2.20 2.41 0.15
2017-06-30 0.74 -1.84 2.24 0.04
2016-12-31 0.38 -21.48 2.29 0.05
2016-09-30 0.28 -21.20 2.12 0.02
2016-06-30 0.18 -20.92 1.95
2015-12-31 0.12 -0.81 1.18
2013-12-31 0.10 0.00 0.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Invitrocue has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Invitrocue has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Invitrocue improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Invitrocue's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Invitrocue has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IVQ Health

 How is Invitrocue's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Invitrocue's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Invitrocue's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Invitrocue's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Invitrocue's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Invitrocue has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Invitrocue Company Filings, last reported 4 months ago.

ASX:IVQ Past Debt and Equity Data
Date (Data in SGD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 -1.25 1.27 0.41
2019-03-31 -1.25 1.27 0.41
2018-12-31 0.50 0.48 1.15
2018-09-30 0.50 0.48 1.15
2018-06-30 2.34 0.42 2.34
2018-03-31 2.34 0.42 2.34
2017-12-31 0.98 0.00 1.56
2017-09-30 0.98 0.00 1.56
2017-06-30 0.09 0.55 0.62
2016-12-31 0.21 0.00 0.91
2016-09-30 0.21 0.00 0.91
2016-06-30 1.22 0.47 1.79
2015-12-31 -0.22 0.46 0.04
2013-12-31 0.00 0.15 0.07
  • Invitrocue has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Invitrocue's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Invitrocue has less than a year of cash runway based on current free cash flow.
  • Invitrocue has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.6% each year.
X
Financial health checks
We assess Invitrocue's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Invitrocue has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IVQ Dividends

 What is Invitrocue's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Invitrocue dividends.
If you bought A$2,000 of Invitrocue shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Invitrocue's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Invitrocue's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:IVQ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 58 Stocks 2.2%
Australia Market Average Dividend Yield Market Cap Weighted Average of 391 Stocks 4.2%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Invitrocue has not reported any payouts.
  • Unable to verify if Invitrocue's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Invitrocue's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Invitrocue has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Invitrocue's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Invitrocue afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Invitrocue has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IVQ Management

 What is the CEO of Invitrocue's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steven Fang
COMPENSATION SGD273,504
CEO Bio

Dr. Sing Boon Fang, also known as Steven, Ph.D., MBA, CIM (UK) founded Invitrocue Limited in March 2014 and also serves as its Managing Director and has been its Executive Director since March 2014. He has been Executive Chairman of Invitrocue Limited since January 9, 2019. Dr. Fang has been a Partner of Clearbridge Accelerator since 2013. He is a Co-Founder of Singapore incorporated Invitrocue Pte Ltd. He was the Chief Executive Officer and Executive Director at CapBridge Pte Ltd. He holds entrepreneurial and business experience within the biomedical sector, together with extensive linkages across Asia. He is very active within Singapore’s entrepreneurship and biomedical sciences sectors. He has a great depth of knowledge of the healthcare provider business and has over 15 years of sales and business development experience in the USA and the Asia Pacific region. He served as the Chief Executive Officer of Life Corporation Ltd from May 1, 2004 to October 3, 2012. He served as the Chief Executive Officer of Cordlife Limited (Formerly Cygenics Ltd.) from 2001 to October 3, 2012. He served as General Manager of Beckton Dickinson from 1996 to 2000, Business Unit Manager at Baxter Inc. from 1991 to 1995 and Business Development Manager at Sterling Pharmaceutical from 1984 to 1990. He founded CordLife Ltd in May 2001 and negotiated the merger with Cytomatrix leading to the establishment of CyGenics earlier this year. He served at Sterling Withthrop, Baxter Healthcare and Becton Dickinson, having undertaken business development assignments in Malaysia, Korea, Taiwan and the Philippines, including the establishment of private dialysis centres. He served as the General Manager of Singapore, Malaysia and Vietnam at Becton Dickinson. He serves as a Co-Chairman Tech-Connect Task Force, Deputy Chairman of Action Community for Entrepreneurship (ACE), & Chairman ACE Mentoring sub-committee, Singapore Ministry of Trade & Industry and Advisory Member of A*STAR ETPL Diagnostic Hotspot Panel. He served as the Chairman of Bio Singapore. He served as the President and Member of Board of Governors of Spirit of Enterprise. He serves as a Director of Clearbridge Accelerator. He is a Member of the Pro-Enterprise Panel, which aims to actively solicit feedback on rules and regulations that hinder businesses and stifle entrepreneurship. He is a Founding Council Member/Past Chairman BioSingapore, an industry association for life sciences businesses in Singapore. He served as a Non-Executive Director of Cordlife Limited from October 3, 2012 to November 19, 2012 and served as its Executive Director from February 19, 2004 to 3, 2012. He served as an Executive Director of Life Corporation Ltd from February 19, 2004 to October 3, 2012 and also served as its Non-Executive Director from October 3, 2012 to November 19, 2012. He served as a Director of Bunuru Corporation Limited since November 6, 2015. He has also received a number of awards, including the Technology Pioneer Award – Life Science, Ernst & Young Entrepreneur of the Year (New Enterprise), Spirit of Enterprise and the Asia Pacific Entrepreneurship Award’s Outstanding Entrepreneur Award. Dr. Fang holds a First Degree in Computer Engineering and CIM(UK) and an M.B.A. with the University of Hull (U.K.) in Business Strategy. He holds a Doctorate in Business Administration from University of South Australia, Master of Business Administration from INSEAD and Master of Business Administration from Tsinghua University.

CEO Compensation
  • Steven's compensation has increased whilst company is loss making.
  • Steven's remuneration is about average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Invitrocue management team in years:

2.2
Average Tenure
  • The tenure for the Invitrocue management team is about average.
Management Team

Steven Fang

TITLE
Founder
COMPENSATION
SGD274K

Andreas Lindner

TITLE
CEO of Europe & Director
COMPENSATION
SGD88K
TENURE
1 yrs

Chow Yee Koh

TITLE
Company Secretary
COMPENSATION
SGD111K
TENURE
4.4 yrs

Martin D. Bach

TITLE
Vice President of Operation
TENURE
3.4 yrs

Sunny Tan

TITLE
Senior Vice President of Scientific Affairs & Business Development
TENURE
2.2 yrs

Arial Yi

TITLE
Scientific Consultant
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure of the Invitrocue board of directors in years:

0.8
Average Tenure
  • The average tenure for the Invitrocue board of directors is less than 3 years, this suggests a new board.
Board of Directors

Andreas Lindner

TITLE
CEO of Europe & Director
COMPENSATION
SGD88K
TENURE
1.8 yrs

Narayanan Iyer

TITLE
Chair of Medical Advisory Board
TENURE
1.1 yrs

Steven Fang

TITLE
Founder
COMPENSATION
SGD274K
TENURE
0.8 yrs

David Waugh

TITLE
Clinical & Scientific Advisor
TENURE
1 yrs

Wee Chng

TITLE
Clinical Advisor
TENURE
1.8 yrs

Masakazu Toi

TITLE
Clinical Advisor

Christian Peschel

TITLE
Clinical Advisor
AGE
69
TENURE
0.8 yrs

Stefan Paepke

TITLE
Clinical Advisor
TENURE
0.8 yrs

Jesús Garcia-Foncillas

TITLE
Clinical Advisor
TENURE
0.8 yrs

Sharifuddin Bin Wahab

TITLE
Global Insurance Advisor
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
22. Nov 18 Buy Chow Yee Koh Individual 22. Nov 18 22. Nov 18 12,000 A$0.08 A$956
X
Management checks
We assess Invitrocue's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Invitrocue has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IVQ News

Simply Wall St News

What Kind Of Shareholder Appears On The Invitrocue Limited's (ASX:IVQ) Shareholder Register?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Invitrocue is a smaller company with a market capitalization of AU$34m, so it may still be flying under the radar of many institutional investors. … Insider Ownership Of Invitrocue The definition of company insiders can be subjective, and does vary between jurisdictions. … Private companies may also have a strategic interest in the company.

Simply Wall St -

You Might Like Invitrocue Limited (ASX:IVQ) But Do You Like Its Debt?

While small-cap stocks, such as Invitrocue Limited (ASX:IVQ) with its market cap of AU$36m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … the current state of its operations and pathway to profitability.

Simply Wall St -

Do Insiders Own Shares In Invitrocue Limited (ASX:IVQ)?

The big shareholder groups in Invitrocue Limited (ASX:IVQ) have power over the company. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … institutions don't own many shares in the company.

Simply Wall St -

Did Changing Sentiment Drive Invitrocue's Share Price Down By 26%?

Unfortunately the Invitrocue Limited (ASX:IVQ) share price slid 26% over twelve months. … Invitrocue recorded just S$592,618 in revenue over the last twelve months, which isn't really enough for us to consider it to have a proven product. … As a general rule, if a company doesn't have revenue, and it loses money, then it is a high risk investment.

Simply Wall St -

Is Invitrocue Limited (ASX:IVQ) A Volatile Stock?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What Kind Of Shareholder Owns Most Invitrocue Limited (ASX:IVQ) Stock?

The big shareholder groups in Invitrocue Limited (ASX:IVQ) have power over the company. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … With a market capitalization of AU$46m, Invitrocue is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Why Invitrocue Limited's (ASX:IVQ) Ownership Structure Is Important

Today, I will be analyzing Invitrocue Limited’s (ASX:IVQ) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … Therefore, it is beneficial for us to examine IVQ's ownership structure in more detail.

Simply Wall St -

Interested In Healthcare? Why Invitrocue Limited (ASX:IVQ) May Be The Entry Point

Healthcare analysts are forecasting for the entire industry, negative growth in the upcoming year , and an overall negative growth rate in the next couple of years. … Unsuprisingly, this is below the growth rate of the Australian stock market as a whole. … Below, I will examine the sector growth prospects, and also determine whether Invitrocue is a laggard or leader relative to its healthcare sector peers.

Simply Wall St -

What Are The Drivers Of Invitrocue Limited's (ASX:IVQ) Risks?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … IVQ, with its market capitalisation of A$41.26M, is a small-cap stock, which generally have higher beta than similar companies of larger size. … How IVQ's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Invitrocue Limited (ASX:IVQ)'s Earnings Grew 94.8%, Is It Enough?

I use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Invitrocue, the most recent bottom-line -SGD1.8M, which, in comparison to last year’s level, has become less negative. … Though Invitrocue's past data is helpful, it is only one aspect of my investment thesis.

Simply Wall St -

IVQ Company Info

Description

Invitrocue Limited provides healthcare bio-analytics solutions primarily in Australia, China, Hong Kong, and Germany. Its bio-analytics solutions include in vitro cell-based testing technologies and image analytics software for use in digital pathology. The company develops Onco Patient-Derived Organoid (PDO) test, a personalize cancer treatment for cancer patients; and 3D CelluSponge series, a 3D in-vitro platform technology for various applications, including 3D cell culture, hepatocyte culture, in-vitro drug metabolism and pharmacokinetic (DMPK) and toxicology, stem cell differentiation, PDO, and pathogen infection and detection applications. It also provides in-vitro DMPK services; in vitro toxicology and safety pharmacology services to assess drug safety profiles early in the discovery process; and customized assays and disease modelling services. Invitrocue Limited is headquartered in Singapore.

Details
Name: Invitrocue Limited
IVQ
Exchange: ASX
Founded:
A$34,709,214
578,486,901
Website: http://www.invitrocue.com
Address: Invitrocue Limited
11 Biopolis Way,
Helios No.12-07/08,
Singapore,
138667,
Singapore
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX IVQ Ordinary Shares Australian Securities Exchange AU AUD 23. May 2008
CHIA IVQ Ordinary Shares Chi-X Australia AU AUD 23. May 2008
ASX IVQ Old Ordinary Shares Australian Securities Exchange AU AUD 05. Nov 2019
Number of employees
Current staff
Staff numbers
0
Invitrocue employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/05 10:31
End of day share price update: 2019/08/08 00:00
Last earnings filing: 2019/10/02
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.